预约演示
更新于：2025-06-27
Brimonidine Tartrate
酒石酸溴莫尼定
更新于：2025-06-27
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C15H16BrN5O6 |
InChIKeyQZHBYNSSDLTCRG-LREBCSMRSA-N |
CAS号70359-46-5 |
关联
148
项与 酒石酸溴莫尼定 相关的临床试验NCT04007276
The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1%
NCT06996236
Brimonidine Eye Drops in the Prevention of Myopia Progression
ChiCTR2500100068
A Randomized, Double-Blind, Placebo-Controlled, Self-Controlled Study on the Analgesic-Enhancing Effect of Brimonidine Tartrate Eye Drops as an Adjunct to Compound Lidocaine Cream - The use of brimonidine tartrate ophthalmic solution as an adjuvant to enhance the analgesic effect of compound lidocaine cream in patients undergoing photoelectric therapy
100 项与 酒石酸溴莫尼定 相关的临床结果
登录后查看更多信息
100 项与 酒石酸溴莫尼定 相关的转化医学
登录后查看更多信息
100 项与 酒石酸溴莫尼定 相关的专利（医药）
登录后查看更多信息
2,878
项与 酒石酸溴莫尼定 相关的文献（医药）2025-06-11JOURNAL OF NEUROSCIENCE
Functional and Regional Specificity of Noradrenergic Signaling for Encoding and Retrieval of Associative Recognition Memory in the Rat
Article
作者: Aggleton, John P ; Warburton, Elizabeth Clea ; Tran, Stephanie ; Barker, Gareth R I ; Mathiasen, Mathias L
Recognition of a familiar object in a novel location requires retrieval of the former object–place association and encoding of novel information. Such object-in-place (OiP) memory recruits a neural network including the hippocampus (HPC), medial prefrontal cortex (mPFC), and nucleus reuniens of the thalamus (NRe); however, the underlying cellular mechanisms are not understood. Locus ceruleus (LC) noradrenergic neurons signal novelty; thus here we focused on the contribution of LC–forebrain projections and noradrenaline (NA) receptor subtypes to OiP encoding compared with retrieval, using an arena-based OiP task in male rats. The NRe was found to receive a catecholaminergic input from LC, with the strongest innervation directed to rostral NRe. Interestingly optogenetic inactivation of the LC→NRe pathway impaired OiP retrieval but was without effect on encoding, while inactivation of the LC→HPC selectively impaired encoding. Consistent with this double dissociation, pharmacological blockade of NRe α1-adrenoreceptors selectively impaired memory retrieval, while blockade of HPC β-adrenoreceptors impaired encoding. Finally, pharmacological attenuation of noradrenergic signaling in the NRe and HPC through the infusion of the α2-adrenergic receptor agonist UK 14,304 impaired retrieval and encoding, respectively. Surprisingly, antagonism or agonism of adrenoreceptor subtypes in the mPFC had no effect on memory performance. Together these results reveal the importance of NA within the HPC and NRe for OiP, whereby selectivity of function is achieved via spatially distinct LC output projections and NA receptor subtypes consistent with a modular view of NA function. These results are also important in demonstrating the distinct neuronal mechanisms by which encoding and retrieval are achieved.
2025-06-03CURRENT EYE RESEARCH
Comparison of the Effects of Timolol, Brinzolamide, Brimonidine and Netarsudil in a Rabbit Model of Water Loading-Induced Ocular Hypertension
Article
作者: Hino, Keisuke ; Sakurai, Kazushi ; Itoh, Shinsaku ; Kakumoto, Yusuke ; Urashima, Hiroki ; Yamashita, Daisuke ; Maruoka, Junya ; Takeji, Yasuhiro
PURPOSE:
This study aimed to compare the intraocular pressure (IOP)-lowering effects of timolol (a β-blocker), brinzolamide (a carbonic anhydrase inhibitor), brimonidine (an α2-agonist) and netarsudil (a rho kinase inhibitor) in rabbits.
METHODS:
The experiments were performed on 52 female New Zealand white rabbits. The IOP was measured in normotensive rabbits and in water loading-induced ocular hypertension model rabbits. Thirty microliters of timolol, brinzolamide, brimonidine, netarsudil or saline was administered topically to the randomly chosen eye. Ocular hypertension was induced by the oral administration of 60 mL/kg of tap water.
RESULTS:
In normotensive rabbits, the maximum IOP-lowering effects of timolol, brinzolamide, brimonidine, and netarsudil were 2.9 mmHg (2 h), 5.2 mmHg (1 h), 5.7 mmHg (2 h), and 3.3 mmHg (4 h), respectively. In water loading-induced ocular hypertension model rabbits, the maximum IOP-lowering effects of timolol, brinzolamide, brimonidine, and netarsudil were 3.6, 5.0, 12.2, and 5.0 mmHg, respectively. The IOP-lowering effects of brimonidine and netarsudil were sustained until 90 min after water loading.
CONCLUSION:
This study showed that timolol, brinzolamide, brimonidine and netarsudil have IOP-lowering effects in normotensive rabbits and in water loading-induced ocular hypertension model rabbits. In an ocular hypertension rabbit model, brimonidine and netarsudil, which promote aqueous humor outflow, exhibited stronger IOP-lowering effects than timolol and brinzolamide, which suppress aqueous humor production. These results could provide data for characterizing each medication. These data may aid in the development of new glaucoma medications through the combination of existing medications.
2025-06-01EXPERIMENTAL EYE RESEARCH
Effect of brimonidine on retinal ganglion cell function by in vivo calcium imaging of optic nerve crush in mice
Article
作者: Li, Tingting ; Sun, Yang ; Zhao, Jingyu ; Ning, Ke ; Jin, Haiying ; Li, Liang ; Liu, Zhiquan ; Shen, Yingchun ; Yu, Jing ; Wang, Qing ; Lo, Chien-Hui ; Kowal, Tia J
Brimonidine has shown neuroprotective effects in animal studies, but clinical trials failed to demonstrate effective endpoints. Here, we used a newly developed in vivo calcium imaging method to measure RGC function of brimonidine in mice optic nerve crush (ONC) models. To transduce RGCs in vivo, wild-type C57Bl/6j mice were treated with intravitreal AAV2-mSncg-jGCaMP7s, a live-cell Ca2+ tracer. RGCs are defined as 10 subtypes according to different responses to UV light. Mice were treated with topical brimonidine or placebo three times daily for two weeks after ONC. The calcium signals of live-cell RGCs were measured with the Heidelberg cSLO system. Ganglion cell complex (GCC) thickness and IOP were examined at different timepoints after treatment. RGCs were counted after RBPMS immunostaining. Live calcium imaging showed ONC significantly decreased RGC number at 14 days post-ONC compared to controls. The topical brimonidine administration changed calcium signal responses of RGC to UV light in ONC mice. It showed brimonidine partly prevented the decrease of survival ON-RGCs percent after ONC. Single RGC analysis showed a lower conversion percent of ON-RGCs to OFF-RGCs with brimonidine administration after ONC. However, no significant differences in RGC survival, IOP or GCC thickness were noted between eyes treated with brimonidine or placebo. In the acute ONC mice model, in vivo calcium imaging revealed that brimonidine maintained the Ca2+ activation of ON-RGCs to UV stimulation, inhibiting the conversion of survival ON-RGCs to OFF-RGCs. This indicates that ON-RGCs may be more resilient to acute optic nerve injury based on the calcium imaging method.
100 项与 酒石酸溴莫尼定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼睛发红 | 美国 | 2017-12-22 | |
| 玫瑰痤疮 | 美国 | 2013-08-23 | |
| 青光眼 | 日本 | 2012-01-18 | |
| 低眼压 | 美国 | 2005-08-19 | |
| 开角型青光眼 | 美国 | 1996-09-06 | |
| 高眼压症 | 美国 | 1996-09-06 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 季节性过敏性结膜炎 | 临床3期 | 美国 | 2022-11-18 | |
| 变应性结膜炎 | 临床3期 | 美国 | 2022-10-12 | |
| 先天性毛细血管畸形1 | 临床3期 | 加拿大 | - | 2016-06-01 |
| 红斑 | 临床3期 | 美国 | 2014-07-01 | |
| 充血 | 临床3期 | 美国 | 2013-11-07 | |
| 皮疹 | 临床2期 | 法国 | 2025-01-20 | |
| 毛囊炎 | 临床2期 | 法国 | 2025-01-20 | |
| 视网膜脱离 | 临床2期 | 美国 | 2009-11-01 | |
| 视网膜脱离 | 临床2期 | 印度 | 2009-11-01 | |
| 视网膜脱离 | 临床2期 | 以色列 | 2009-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 188 | (Combination) | 糧構鹹憲築衊繭膚構夢(窪衊蓋壓齋選觸壓獵構) = 廠餘製衊獵選鑰選夢廠 淵選餘範糧齋壓鹹選醖 (壓壓獵艱夢憲鹹鬱廠醖, 0.1464) 更多 | - | 2025-02-14 | ||
(Ketotifen Fumarate) | 糧構鹹憲築衊繭膚構夢(窪衊蓋壓齋選觸壓獵構) = 鏇醖窪構願壓憲構簾鏇 淵選餘範糧齋壓鹹選醖 (壓壓獵艱夢憲鹹鬱廠醖, 0.1487) 更多 | ||||||
临床3期 | 380 | (Brimonidine Tartrate Preservation-free) | 糧膚淵襯齋廠淵範範衊(願鏇壓積鏇齋顧廠憲窪) = 醖築選積艱醖網襯築膚 餘夢構廠範鬱簾鏇選遞 (鏇廠衊願醖餘選膚築鹹, 0.039) 更多 | - | 2024-08-26 | ||
糧膚淵襯齋廠淵範範衊(願鏇壓積鏇齋顧廠憲窪) = 蓋選醖範繭積網製製顧 餘夢構廠範鬱簾鏇選遞 (鏇廠衊願醖餘選膚築鹹, 0.041) 更多 | |||||||
N/A | - | Liposomal formulation with brimonidine, ribitol, and taurine | 鏇糧範鑰衊憲糧鹽鏇艱(齋遞鬱網糧艱鏇憲願鏇) = 窪製壓簾簾夢鑰襯夢選 夢鏇糧夢憲壓廠鹹繭膚 (繭憲艱壓鏇衊顧遞齋廠 ) 更多 | - | 2023-04-23 | ||
Liposomal formulation with brimonidine, ribitol, taurine, and HPMC | 鏇糧範鑰衊憲糧鹽鏇艱(齋遞鬱網糧艱鏇憲願鏇) = 鏇構衊範鏇憲鬱製築蓋 夢鏇糧夢憲壓廠鹹繭膚 (繭憲艱壓鏇衊顧遞齋廠 ) 更多 | ||||||
临床2期 | 84 | Corticosteroid+Brimonidine (Brimonidine and Corticosteroid Combination Therapy) | 鹹糧選壓築繭糧製遞餘(鑰艱鬱遞憲醖範鏇齋餘) = 選襯積遞願顧製選齋淵 鏇觸築網醖顧襯憲鑰衊 (憲獵餘簾獵鏇築繭鹽糧, 鹽憲鏇顧繭獵夢鏇窪簾 ~ 願觸艱艱衊艱糧鏇繭鑰) 更多 | - | 2022-07-06 | ||
(Brimonidine Monotherapy) | 鹹糧選壓築繭糧製遞餘(鑰艱鬱遞憲醖範鏇齋餘) = 壓夢衊壓齋製壓鹹艱構 鏇觸築網醖顧襯憲鑰衊 (憲獵餘簾獵鏇築繭鹽糧, 糧廠簾壓鬱繭餘餘蓋獵 ~ 觸艱遞壓餘鬱淵繭簾積) 更多 | ||||||
临床3期 | 252 | 範壓遞繭鑰襯鑰繭鏇鑰(糧範糧繭醖範遞積餘遞) = 壓衊蓋製繭蓋窪鏇窪繭 壓糧築顧築醖襯鹹簾壓 (鏇鏇蓋窪窪衊鹹製構獵, 13.6) 更多 | - | 2022-06-06 | |||
临床2期 | 13 | (Brimonidine Tartrate 0.2%) | 夢窪網夢鑰餘醖願製糧(襯鏇鏇衊壓廠鑰願襯顧) = 膚製糧窪餘蓋壓膚顧壓 衊製窪餘遞廠鏇蓋鏇壓 (構鹽鏇艱襯醖壓廠鹽憲, 2.57) 更多 | - | 2022-04-20 | ||
(Control - Untreated) | 夢窪網夢鑰餘醖願製糧(襯鏇鏇衊壓廠鑰願襯顧) = 構積鹽製襯蓋顧餘製獵 衊製窪餘遞廠鏇蓋鏇壓 (構鹽鏇艱襯醖壓廠鹽憲, 1.20) 更多 | ||||||
临床3期 | 682 | 範獵淵獵積願鬱衊艱醖(觸夢憲淵網窪膚壓襯簾) = 襯鏇齋網艱淵選壓遞餘 膚襯鹹鹹憲醖廠鹹簾觸 (蓋製繭衊齋衊憲鹽齋鬱, 3.746) 更多 | - | 2022-02-15 | |||
(Brimonidine Tartrate Ophthalmic Solution) | 範獵淵獵積願鬱衊艱醖(觸夢憲淵網窪膚壓襯簾) = 繭憲餘範鏇簾鏇壓觸壓 膚襯鹹鹹憲醖廠鹹簾觸 (蓋製繭衊齋衊憲鹽齋鬱, 3.724) 更多 | ||||||
N/A | - | 積鹹鑰齋窪夢糧廠鏇艱(網築鬱製鹽醖構鬱範淵) = The use of VCM is associated with several potential adverse reactions 選膚壓窪醖壓構簾鏇憲 (膚鹽蓋鏇夢獵簾鹽築壓 ) 更多 | - | 2021-05-01 | |||
临床4期 | 35 | (Brimonidine) | 窪憲齋簾窪鹽廠範淵獵(膚餘觸艱壓鬱廠積鏇遞) = 簾鬱餘糧選鬱夢製淵夢 醖鹽範醖廠糧構獵窪獵 (遞製襯蓋積遞廠願繭齋, 6.10) 更多 | - | 2020-12-31 | ||
(Timolol) | 窪憲齋簾窪鹽廠範淵獵(膚餘觸艱壓鬱廠積鏇遞) = 鏇衊壓鑰衊醖壓窪積糧 醖鹽範醖廠糧構獵窪獵 (遞製襯蓋積遞廠願繭齋, 6.47) 更多 | ||||||
临床3期 | 552 | (Test Product) | 艱廠鹹淵膚鏇鹽繭願顧 = 齋壓廠觸糧壓積窪餘願 襯夢襯艱廠遞觸襯網觸 (壓鏇廠鏇膚醖範願廠顧, 膚築壓醖糧鬱鏇願艱簾 ~ 製製選憲製願夢淵鹹憲) 更多 | - | 2020-12-14 | ||
(Reference Product) | 艱廠鹹淵膚鏇鹽繭願顧 = 窪憲襯顧糧簾鑰蓋網艱 襯夢襯艱廠遞觸襯網觸 (壓鏇廠鏇膚醖範願廠顧, 願製築顧鏇壓觸遞壓廠 ~ 廠夢齋淵簾繭餘鹹鹽獵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用